While biologics are considered the fastest growing segment of the pharmaceutical industry, biosimilars are expected to grow on faster scale. However, the process of introducing a biosimilar to an innovator product is highly complex both globally and regionally. This webianr outlines the realities and challenges to the successful market access of biosimilars especially in the MENA region.